Compugen (CGEN) Stock Forecast, Price Target & Predictions
CGEN Stock Forecast
Compugen stock forecast is as follows: an average price target of $4.00 (represents a 103.05% upside from CGEN’s last price of $1.97) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CGEN Price Target
The average price target for Compugen (CGEN) is $4.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 103.05% upside from CGEN's last price of $1.97.
CGEN Analyst Ratings
According to 3 Wall Street analysts, Compugen's rating consensus is 'Buy'. The analyst rating breakdown for CGEN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Compugen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 21, 2024 | Asthika Goonewardene | Truist Financial | $4.00 | $1.74 | 129.89% | 103.05% |
| May 20, 2024 | Stephen Willey | Stifel Nicolaus | $4.00 | $1.74 | 129.89% | 103.05% |
| May 20, 2024 | Asthika Goonewardene | Truist Financial | $5.00 | $1.74 | 187.36% | 153.81% |
The latest Compugen stock forecast, released on May 21, 2024 by Asthika Goonewardene from Truist Financial, set a price target of $4.00, which represents a 129.89% increase from the stock price at the time of the forecast ($1.74), and a 103.05% increase from CGEN last price ($1.97).
Compugen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $4.33 |
| Last Closing Price | $1.97 | $1.97 | $1.97 |
| Upside/Downside | -100.00% | -100.00% | 119.80% |
In the current month, the average price target of Compugen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Compugen's last price of $1.97. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 08, 2023 | Jefferies | - | Underperform | Downgrade |
| Nov 15, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 08, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Feb 25, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 25, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Compugen's last stock rating was published by Jefferies on Feb 08, 2023. The company Downgrade its CGEN rating from "null" to "Underperform".
Compugen Financial Forecast
Compugen Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 21 | Sep 21 | Dec 20 | Sep 18 | Mar 18 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | Dec 15 | Sep 15 | Jun 15 | Mar 15 | Dec 14 | Sep 14 | Jun 14 | Mar 14 | Dec 13 | Sep 13 | Jun 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $6.00M | $2.00M | $7.80M | $10.00M | $53.00K | $70.00K | $496.00K | $93.00K | $8.31M | $229.00K | $223.00K | $513.00K | $6.55M | $1.72M | $1.96M | $2.13M | $1.77M | $1.59M | $800.00K |
| Avg Forecast | $13.09M | $11.71M | $10.47M | $9.37M | $11.66M | $1.28M | $1.66M | $2.42M | $20.00M | $3.75M | $1.00M | $7.65M | $2.00M | $23.40M | $18.09M | $50.00K | $60.67K | $617.65K | $79.41K | $91.41M | $265.38K | $188.57K | $425.00K | $10.18M | $1.72M | $4.31M | $5.33M | $2.27M | $1.32M | $1.60M |
| High Forecast | $20.90M | $18.70M | $16.72M | $14.96M | $18.62M | $2.37M | $2.65M | $3.87M | $31.94M | $5.99M | $1.00M | $9.18M | $2.40M | $28.08M | $21.71M | $60.00K | $72.80K | $741.18K | $95.29K | $109.69M | $318.46K | $226.28K | $510.00K | $12.22M | $2.06M | $5.17M | $6.39M | $2.72M | $1.59M | $1.92M |
| Low Forecast | $1.88M | $1.68M | $1.50M | $1.34M | $1.67M | $185.44K | $238.18K | $347.59K | $2.87M | $537.51K | $1.00M | $6.12M | $1.60M | $18.72M | $14.47M | $40.00K | $48.53K | $494.12K | $63.53K | $73.13M | $212.31K | $150.86K | $340.00K | $8.15M | $1.38M | $3.45M | $4.26M | $1.82M | $1.06M | $1.28M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 6 | 13 | 9 | 10 | 9 | 7 | 18 | 15 | 19 | 9 | 8 | 11 | 18 | 18 | 15 | 18 | 13 | 17 | 10 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.78% | 1.00% | 0.33% | 0.55% | 1.06% | 1.15% | 0.80% | 1.17% | 0.09% | 0.86% | 1.18% | 1.21% | 0.64% | 1.00% | 0.46% | 0.40% | 0.78% | 1.20% | 0.50% |
Compugen's average Quarter revenue forecast for Dec 21 based on 6 analysts is $1.00M, with a low forecast of $1.00M, and a high forecast of $1.00M. CGEN's average Quarter revenue forecast represents a -83.33% decrease compared to the company's last Quarter revenue of $6.00M (Sep 21).
Compugen EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 21 | Sep 21 | Dec 20 | Sep 18 | Mar 18 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | Dec 15 | Sep 15 | Jun 15 | Mar 15 | Dec 14 | Sep 14 | Jun 14 | Mar 14 | Dec 13 | Sep 13 | Jun 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 6 | 13 | 9 | 10 | 9 | 7 | 18 | 15 | 19 | 9 | 8 | 11 | 18 | 18 | 15 | 18 | 13 | 17 | 10 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-8.78M | $-6.33M | $-9.09M | $-3.33M | $115.00K | $-8.74M | $-7.97M | $-7.01M | $-8.87M | $-727.00K | $-6.91M | $-6.95M | $-6.32M | $-1.11M | $-4.59M | $-3.32M | $-3.31M | $-3.96M | $-4.40M | $-937.00K |
| Avg Forecast | $-6.22M | $-5.56M | $-4.97M | $-4.45M | $-5.54M | $-607.76K | $-788.98K | $-1.15M | $-9.50M | $-1.78M | $-11.29M | $-7.85M | $-8.56M | $-4.33M | $162.82K | $-8.24M | $-6.42M | $-6.81M | $-7.22M | $2.06M | $-7.45M | $-5.15M | $-4.77M | $-1.32M | $-6.20M | $-1.31M | $-705.60K | $-1.36M | $-3.82M | $-1.16M |
| High Forecast | $-890.87K | $-796.82K | $-712.70K | $-637.46K | $-793.67K | $-88.05K | $-113.09K | $-165.04K | $-1.36M | $-255.22K | $-9.03M | $-6.28M | $-6.85M | $-3.47M | $195.38K | $-6.59M | $-5.14M | $-5.45M | $-5.78M | $2.47M | $-5.96M | $-4.12M | $-3.81M | $-1.06M | $-4.96M | $-1.05M | $-564.48K | $-1.09M | $-3.05M | $-928.80K |
| Low Forecast | $-9.92M | $-8.88M | $-7.94M | $-7.10M | $-8.84M | $-1.13M | $-1.26M | $-1.84M | $-15.16M | $-2.84M | $-13.55M | $-9.42M | $-10.28M | $-5.20M | $130.25K | $-9.89M | $-7.71M | $-8.17M | $-8.66M | $1.65M | $-8.94M | $-6.18M | $-5.72M | $-1.59M | $-7.44M | $-1.57M | $-846.72K | $-1.64M | $-4.58M | $-1.39M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.78% | 0.81% | 1.06% | 0.77% | 0.71% | 1.06% | 1.24% | 1.03% | 1.23% | -0.35% | 0.93% | 1.35% | 1.33% | 0.84% | 0.74% | 2.54% | 4.69% | 2.90% | 1.15% | 0.81% |
10 analysts predict CGEN's average Quarter EBITDA for Sep 18 to be $-4.33M, with a high of $-3.47M and a low of $-5.20M. This is -3869.57% lower than Compugen's previous annual EBITDA (Mar 18) of $115.00K.
Compugen Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 21 | Sep 21 | Dec 20 | Sep 18 | Mar 18 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | Dec 15 | Sep 15 | Jun 15 | Mar 15 | Dec 14 | Sep 14 | Jun 14 | Mar 14 | Dec 13 | Sep 13 | Jun 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 6 | 13 | 9 | 10 | 9 | 7 | 18 | 15 | 19 | 9 | 8 | 11 | 18 | 18 | 15 | 18 | 13 | 17 | 10 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-8.38M | $-5.80M | $-7.58M | $-2.67M | $82.00K | $-8.39M | $-7.41M | $-6.13M | $-8.06M | $-472.00K | $-6.40M | $-6.52M | $-5.79M | $-1.48M | $-7.00M | $-2.32M | $928.00K | $-2.93M | $-4.74M | $-855.00K |
| Avg Forecast | $-8.06M | $-8.06M | $-8.95M | $-8.95M | $1.79M | $-8.51M | $-7.76M | $-9.85M | $9.25M | $-8.95M | $-11.12M | $-7.85M | $-8.56M | $-4.67M | $180.91K | $-8.49M | $-6.58M | $-8.19M | $-7.45M | $-807.54K | $-7.64M | $-5.67M | $-4.91M | $-2.30M | $-5.40M | $-3.23M | $-2.74M | $-3.74M | $-3.79M | $-1.22M |
| High Forecast | $915.87K | $915.87K | $1.02M | $1.02M | $3.18M | $14.18M | $881.95K | $1.12M | $52.73M | $1.02M | $-8.89M | $-6.28M | $-6.85M | $-3.73M | $217.09K | $-6.79M | $-5.27M | $-6.55M | $-5.96M | $-646.04K | $-6.11M | $-4.54M | $-3.93M | $-1.84M | $-4.32M | $-2.58M | $-2.19M | $-2.99M | $-3.03M | $-972.00K |
| Low Forecast | $-14.31M | $-14.31M | $-15.90M | $-15.90M | $-203.53K | $-29.77M | $-13.78M | $-17.49M | $-12.95M | $-15.90M | $-13.34M | $-9.42M | $-10.28M | $-5.60M | $144.73K | $-10.19M | $-7.90M | $-9.83M | $-8.94M | $-969.05K | $-9.17M | $-6.81M | $-5.89M | $-2.76M | $-6.48M | $-3.87M | $-3.28M | $-4.48M | $-4.55M | $-1.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.74% | 0.89% | 0.57% | 0.45% | 0.99% | 1.13% | 0.75% | 1.08% | 0.58% | 0.84% | 1.15% | 1.18% | 0.64% | 1.30% | 0.72% | -0.34% | 0.78% | 1.25% | 0.70% |
Compugen's average Quarter net income forecast for Sep 18 is $-4.67M, with a range of $-5.60M to $-3.73M. CGEN's average Quarter net income forecast represents a -5790.85% decrease compared to the company's last Quarter net income of $82.00K (Mar 18).
Compugen SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 21 | Sep 21 | Dec 20 | Sep 18 | Mar 18 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | Dec 15 | Sep 15 | Jun 15 | Mar 15 | Dec 14 | Sep 14 | Jun 14 | Mar 14 | Dec 13 | Sep 13 | Jun 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 6 | 13 | 9 | 10 | 9 | 7 | 18 | 15 | 19 | 9 | 8 | 11 | 18 | 18 | 15 | 18 | 13 | 17 | 10 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $2.94M | $2.92M | $2.93M | $2.69M | $2.47M | $2.45M | $2.01M | $1.96M | $2.11M | $2.20M | $1.61M | $1.84M | $1.67M | $1.83M | $1.66M | $1.35M | $1.45M | $1.67M | $1.69M | $724.00K |
| Avg Forecast | $26.37M | $23.58M | $21.09M | $18.87M | $23.49M | $2.58M | $3.35M | $4.88M | $40.29M | $7.55M | $2.01M | $3.73M | $4.03M | $4.03M | $4.46M | $100.72K | $122.20K | $1.24M | $159.97K | $3.79M | $534.59K | $379.86K | $856.12K | $2.84M | $1.66M | $1.88M | $2.08M | $2.12M | $2.67M | $970.65K |
| High Forecast | $42.11M | $37.66M | $33.69M | $30.13M | $37.51M | $4.78M | $5.35M | $7.80M | $64.33M | $12.06M | $2.01M | $4.48M | $4.83M | $4.84M | $5.35M | $120.86K | $146.65K | $1.49M | $191.96K | $4.54M | $641.51K | $455.83K | $1.03M | $3.41M | $1.99M | $2.26M | $2.50M | $2.54M | $3.20M | $1.16M |
| Low Forecast | $3.78M | $3.38M | $3.02M | $2.70M | $3.37M | $373.56K | $479.79K | $700.19K | $5.77M | $1.08M | $2.01M | $2.98M | $3.22M | $3.23M | $3.57M | $80.58K | $97.76K | $995.35K | $127.97K | $3.03M | $427.67K | $303.88K | $684.90K | $2.28M | $1.33M | $1.51M | $1.67M | $1.70M | $2.14M | $776.52K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.46% | 0.78% | 0.73% | 0.67% | 0.55% | 24.30% | 16.46% | 1.57% | 13.18% | 0.58% | 3.01% | 4.84% | 1.95% | 0.64% | 1.00% | 0.72% | 0.69% | 0.79% | 0.63% | 0.75% |
Compugen's average Quarter SG&A projection for Sep 23 is $7.55M, based on 1 Wall Street analysts, with a range of $1.08M to $12.06M. The forecast indicates a 157.20% rise compared to CGEN last annual SG&A of $2.94M (Dec 21).
Compugen EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Dec 21 | Sep 21 | Dec 20 | Sep 18 | Mar 18 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | Dec 15 | Sep 15 | Jun 15 | Mar 15 | Dec 14 | Sep 14 | Jun 14 | Mar 14 | Dec 13 | Sep 13 | Jun 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 6 | 13 | 9 | 10 | 9 | 7 | 18 | 15 | 19 | 9 | 8 | 11 | 18 | 18 | 15 | 18 | 13 | 17 | 10 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.07 | $-0.09 | $-0.05 | - | $-0.16 | $-0.15 | $-0.12 | $-0.16 | $-0.01 | $-0.13 | $-0.13 | $-0.11 | $-0.03 | $-0.14 | $-0.05 | $-0.04 | $-0.07 | $-0.12 | $-0.03 |
| Avg Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.10 | $0.02 | $-0.10 | $-0.09 | $-0.11 | $0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.10 | $-0.22 | $-0.34 | $-0.17 | $-0.11 | $-0.21 | $-0.13 | $-0.19 | $-0.17 | $-0.10 | $-0.08 | $-0.17 | $-0.11 | $-0.15 | $-0.14 | $-0.15 | $-0.08 | $-0.08 |
| High Forecast | $0.01 | $0.01 | $0.01 | $0.01 | $0.04 | $0.16 | $0.01 | $0.01 | $0.59 | $0.01 | $-0.13 | $-0.13 | $-0.10 | $-0.18 | $-0.27 | $-0.14 | $-0.09 | $-0.17 | $-0.10 | $-0.15 | $-0.14 | $-0.08 | $-0.06 | $-0.14 | $-0.09 | $-0.12 | $-0.12 | $-0.12 | $-0.06 | $-0.06 |
| Low Forecast | $-0.16 | $-0.16 | $-0.18 | $-0.18 | $-0.00 | $-0.33 | $-0.15 | $-0.20 | $-0.14 | $-0.18 | $-0.13 | $-0.13 | $-0.10 | $-0.27 | $-0.41 | $-0.20 | $-0.13 | $-0.25 | $-0.16 | $-0.23 | $-0.20 | $-0.12 | $-0.10 | $-0.21 | $-0.13 | $-0.18 | $-0.17 | $-0.18 | $-0.10 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.74% | 0.55% | 0.89% | 0.21% | -0.00% | 0.94% | 1.36% | 0.57% | 1.23% | 0.05% | 0.76% | 1.30% | 1.38% | 0.17% | 1.27% | 0.32% | 0.29% | 0.48% | 1.50% | 0.32% |
According to 10 Wall Street analysts, Compugen's projected average Quarter EPS for Sep 18 is $-0.22, with a low estimate of $-0.27 and a high estimate of $-0.18. This represents a -13850.00% decrease compared to CGEN previous annual EPS of - (Mar 18).
Compugen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics | $2.96 | $29.00 | 879.73% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| EVGN | Evogene | $2.88 | $12.00 | 316.67% | Buy |
| CLGN | CollPlant Bio | $5.01 | $14.00 | 179.44% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| ITOS | iTeos Therapeutics | $16.70 | $38.50 | 130.54% | Buy |
| CGEN | Compugen | $1.97 | $4.00 | 103.05% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
CGEN Forecast FAQ
Is Compugen a good buy?
Yes, according to 3 Wall Street analysts, Compugen (CGEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CGEN's total ratings.
What is CGEN's price target?
Compugen (CGEN) average price target is $4 with a range of $4 to $4, implying a 103.05% from its last price of $1.97. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Compugen stock go up soon?
According to Wall Street analysts' prediction for CGEN stock, the company can go up by 103.05% (from the last price of $1.97 to the average price target of $4), up by 103.05% based on the highest stock price target, and up by 103.05% based on the lowest stock price target.
Can Compugen stock reach $3?
CGEN's average twelve months analyst stock price target of $4 supports the claim that Compugen can reach $3 in the near future.
What are Compugen's analysts' financial forecasts?
Compugen's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $17.03M (high $27.52M, low $2.44M), average EBITDA is $-8.085M (high $-1.16M, low $-13.068M), average net income is $-24.323M (high $19.36M, low $-61.243M), average SG&A $34.3M (high $55.44M, low $4.92M), and average EPS is $-0.272 (high $0.216, low $-0.684). CGEN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $44.64M (high $71.28M, low $6.4M), average EBITDA is $-21.194M (high $-3.038M, low $-33.844M), average net income is $-34.022M (high $3.87M, low $-60.42M), average SG&A $89.91M (high $143.58M, low $12.89M), and average EPS is $-0.38 (high $0.0432, low $-0.675).
Did the CGEN's actual financial results beat the analysts' financial forecasts?
Based on Compugen's last annual report (Dec 2021), the company's revenue was $6M, which missed the average analysts forecast of $8.65M by -30.64%. Apple's EBITDA was $-35.074M, beating the average prediction of $-19.137M by 83.27%. The company's net income was $-32.461M, beating the average estimation of $-18.964M by 71.17%. Apple's SG&A was $11.7M, beating the average forecast of $5.74M by 103.70%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.258 by 51.24%. In terms of the last quarterly report (Sep 2021), Compugen's revenue was $6M, missing the average analysts' forecast of $7.65M by -21.57%. The company's EBITDA was $-6.333M, missing the average prediction of $-7.849M by -19.31%. Compugen's net income was $-5.802M, missing the average estimation of $-7.849M by -26.08%. The company's SG&A was $2.92M, missing the average forecast of $3.73M by -21.57%. Lastly, the company's EPS was $-0.0691, missing the average prediction of $-0.125 by -44.72%